Support for an innovative respiratory drug throughout the NICE ILAP process

Our client had recently received Innovation Passport designation for their product, a novel drug for a respiratory condition. This was the first time they had been through the ILAP process. Owing to the relative rarity of the condition in question, our client also required additional evidence generation activities to support the positioning of their product.

We took responsibility for guiding our client through all aspects of the ILAP process, including the drafting of a discussion guide for the HTA Access Forum meeting, attending this meeting, and presenting slides on the disease area and product, and providing ongoing strategic support. Also part of the project was a questionnaire and advisory board with expert clinicians in the disease area, which was used to inform discussions with NICE.

Participating in the HTA Access Forum gave our client valuable insights to inform their preparations for a NICE submission. Additionally, our questionnaire and advisory board have formed part of a broader effort to collect evidence regarding treatment practices in the disease area.